Stockreport

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point [Seeking Alpha]

aTyr Pharma, Inc.  (ATYR) 
PDF Investing Group Leader Follow Summary Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expect [Read more]